
|Videos|November 21, 2022
Dr. Lowentritt discusses phase 3 SPOTLIGHT trial on new PSMA-PET tool
Author(s)Urology Times staff
"The idea that we may have reliable and consistently interpretable tests for these patients is exciting for the future," says Benjamin Lowentritt, MD, FACS.
Advertisement
In this interview, Benjamin Lowentritt, MD, FACS, recaps key findings from the phase 3 SPOTLIGHT trial data that were presented at the 2022 ASTRO Annual Meeting. He is currently a practicing urologist at Chesapeake Urology in Baltimore, Maryland.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5






